Amniocentesis in HIV Pregnant Women: 16 Years of Experience

Detalhes bibliográficos
Autor(a) principal: Simões, M
Data de Publicação: 2013
Outros Autores: Marques, C, Gonçalves, A, Pereira, AP, Correia, J, Castela, J, Guerreiro, C
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.17/1830
Resumo: The iatrogenic risk of HIV vertical transmission, calculated in initial epidemiologic studies, seemed to counterindicate invasive prenatal diagnosis (PND) procedures. The implementation of highly active antiretroviral therapy (HAART) represented a turning point in PND management, owing to a rapid and effective reduction of maternal viral load (VL). In the present study, we identified cases of vertical transmission in HIV-infected pregnant women who did amniocentesis in the second trimester of pregnancy (n = 27), from 1996 to 2011. We divided our sample into Group A--women under HAART when submitted to amniocentesis (n = 20) and Group B--women without antiretroviral therapy before amniocentesis (n = 7). We had 1 case of vertical transmission in Group B. Preconceptional or early first trimester HIV serology is essential to avoid performing an amniocentesis without antiretroviral therapy or viral suppression. When there is an indication for amniocentesis in an HIV-infected pregnant woman, it should be done if the patient is on HAART and, if possible, when VL is undetectable. Nowadays, with combined first trimester screening test to select pregnancies with high risk of aneuploidies, advanced maternal age is a less frequent indication to perform PND invasive procedures, representing an outstanding gain in prenatal diagnosis of this population.
id RCAP_474a484c526965f12f3fae659fe5e0d1
oai_identifier_str oai:repositorio.chlc.min-saude.pt:10400.17/1830
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Amniocentesis in HIV Pregnant Women: 16 Years of ExperienceMAC GINMAC PEDMAC MED MAFAmniocentesis/adverse effectsAmniocentesis/methodsAmniocentesis/statistics & numerical dataAnti-Retroviral AgentsAnti-Retroviral Therapy, Highly ActiveCohort StudiesHIV InfectionsIatrogenic DiseaseInfectious Disease Transmission, VerticalPregnancyPregnancy Complications, InfectionsPregnancy Trimester, SecondThe iatrogenic risk of HIV vertical transmission, calculated in initial epidemiologic studies, seemed to counterindicate invasive prenatal diagnosis (PND) procedures. The implementation of highly active antiretroviral therapy (HAART) represented a turning point in PND management, owing to a rapid and effective reduction of maternal viral load (VL). In the present study, we identified cases of vertical transmission in HIV-infected pregnant women who did amniocentesis in the second trimester of pregnancy (n = 27), from 1996 to 2011. We divided our sample into Group A--women under HAART when submitted to amniocentesis (n = 20) and Group B--women without antiretroviral therapy before amniocentesis (n = 7). We had 1 case of vertical transmission in Group B. Preconceptional or early first trimester HIV serology is essential to avoid performing an amniocentesis without antiretroviral therapy or viral suppression. When there is an indication for amniocentesis in an HIV-infected pregnant woman, it should be done if the patient is on HAART and, if possible, when VL is undetectable. Nowadays, with combined first trimester screening test to select pregnancies with high risk of aneuploidies, advanced maternal age is a less frequent indication to perform PND invasive procedures, representing an outstanding gain in prenatal diagnosis of this population.Hindawi Publishing CorporationRepositório do Centro Hospitalar Universitário de Lisboa Central, EPESimões, MMarques, CGonçalves, APereira, APCorreia, JCastela, JGuerreiro, C2014-06-19T14:30:14Z20132013-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/1830engInfect Dis Obstet Gynecol. 2013;2013:914272. doi: 10.1155/2013/914272. Epub 2013 Jul 21info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-10T09:33:31Zoai:repositorio.chlc.min-saude.pt:10400.17/1830Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:19:14.669804Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Amniocentesis in HIV Pregnant Women: 16 Years of Experience
title Amniocentesis in HIV Pregnant Women: 16 Years of Experience
spellingShingle Amniocentesis in HIV Pregnant Women: 16 Years of Experience
Simões, M
MAC GIN
MAC PED
MAC MED MAF
Amniocentesis/adverse effects
Amniocentesis/methods
Amniocentesis/statistics & numerical data
Anti-Retroviral Agents
Anti-Retroviral Therapy, Highly Active
Cohort Studies
HIV Infections
Iatrogenic Disease
Infectious Disease Transmission, Vertical
Pregnancy
Pregnancy Complications, Infections
Pregnancy Trimester, Second
title_short Amniocentesis in HIV Pregnant Women: 16 Years of Experience
title_full Amniocentesis in HIV Pregnant Women: 16 Years of Experience
title_fullStr Amniocentesis in HIV Pregnant Women: 16 Years of Experience
title_full_unstemmed Amniocentesis in HIV Pregnant Women: 16 Years of Experience
title_sort Amniocentesis in HIV Pregnant Women: 16 Years of Experience
author Simões, M
author_facet Simões, M
Marques, C
Gonçalves, A
Pereira, AP
Correia, J
Castela, J
Guerreiro, C
author_role author
author2 Marques, C
Gonçalves, A
Pereira, AP
Correia, J
Castela, J
Guerreiro, C
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE
dc.contributor.author.fl_str_mv Simões, M
Marques, C
Gonçalves, A
Pereira, AP
Correia, J
Castela, J
Guerreiro, C
dc.subject.por.fl_str_mv MAC GIN
MAC PED
MAC MED MAF
Amniocentesis/adverse effects
Amniocentesis/methods
Amniocentesis/statistics & numerical data
Anti-Retroviral Agents
Anti-Retroviral Therapy, Highly Active
Cohort Studies
HIV Infections
Iatrogenic Disease
Infectious Disease Transmission, Vertical
Pregnancy
Pregnancy Complications, Infections
Pregnancy Trimester, Second
topic MAC GIN
MAC PED
MAC MED MAF
Amniocentesis/adverse effects
Amniocentesis/methods
Amniocentesis/statistics & numerical data
Anti-Retroviral Agents
Anti-Retroviral Therapy, Highly Active
Cohort Studies
HIV Infections
Iatrogenic Disease
Infectious Disease Transmission, Vertical
Pregnancy
Pregnancy Complications, Infections
Pregnancy Trimester, Second
description The iatrogenic risk of HIV vertical transmission, calculated in initial epidemiologic studies, seemed to counterindicate invasive prenatal diagnosis (PND) procedures. The implementation of highly active antiretroviral therapy (HAART) represented a turning point in PND management, owing to a rapid and effective reduction of maternal viral load (VL). In the present study, we identified cases of vertical transmission in HIV-infected pregnant women who did amniocentesis in the second trimester of pregnancy (n = 27), from 1996 to 2011. We divided our sample into Group A--women under HAART when submitted to amniocentesis (n = 20) and Group B--women without antiretroviral therapy before amniocentesis (n = 7). We had 1 case of vertical transmission in Group B. Preconceptional or early first trimester HIV serology is essential to avoid performing an amniocentesis without antiretroviral therapy or viral suppression. When there is an indication for amniocentesis in an HIV-infected pregnant woman, it should be done if the patient is on HAART and, if possible, when VL is undetectable. Nowadays, with combined first trimester screening test to select pregnancies with high risk of aneuploidies, advanced maternal age is a less frequent indication to perform PND invasive procedures, representing an outstanding gain in prenatal diagnosis of this population.
publishDate 2013
dc.date.none.fl_str_mv 2013
2013-01-01T00:00:00Z
2014-06-19T14:30:14Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.17/1830
url http://hdl.handle.net/10400.17/1830
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Infect Dis Obstet Gynecol. 2013;2013:914272. doi: 10.1155/2013/914272. Epub 2013 Jul 21
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hindawi Publishing Corporation
publisher.none.fl_str_mv Hindawi Publishing Corporation
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131289922568192